| Literature DB >> 26089598 |
Katsuhiko Naruse1, Juria Akasaka1, Aiko Shigemitsu1, Taihei Tsunemi1, Natsuki Koike1, Chiharu Yoshimoto1, Hiroshi Kobayashi1.
Abstract
OBJECTIVES: The pathophysiology of preeclampsia is characterized by abnormal placentation, an exaggerated inflammatory response, and generalized dysfunction of the maternal endothelium. We investigated the effects of preeclampsia serum on the expression of inflammation-related genes by adipose tissue.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26089598 PMCID: PMC4458290 DOI: 10.1155/2015/325932
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Characteristics of the study population of the sera.
| Normal pregnancy | Preeclampsia | |
|---|---|---|
|
| 5 | 5 |
| Maternal age at sampling (years) | 31.8 ± 2.1 | 31.5 ± 2.9 |
| Gestational age at sampling (weeks+days, range) | 28+0 (27+1–28+4) | 29+1 (26+5–31+3) |
| BMI at sampling (kg/m2) | 24.1 ± 1.6 | 23.5 ± 0.5 |
| BMI before pregnancy (kg/m2) | 22.7 ± 2.3 | 20.6 ± 0.4 |
| Blood pressure (mm/Hg) | ||
| Systolic | 121.2 ± 1.9 | 182.8 ± 5.7 |
| Diastolic | 67.8 ± 1.9 | 117.2 ± 3.4 |
| MAP | 85.6 ± 1.7 | 139.1 ± 3.9 |
BMI: body mass index; MAP: mean arterial pressure. All patients in preeclampsia group showed urine protein over 2 g/day. Data has shown as mean ± S.E.M. unless indicated.
P < 0.05 versus normal pregnancy.
Figure 1Genes identified with altered expression in adipose tissues treated with preeclampsia sera. Thirty genes showed alteration at least 2-fold or statistical significance (P < 0.05, unpaired t-test). Black diamond shows mean and open bars show 95% CI of respective genes.
Genes identified with altered expression in adipose tissues treated with preeclampsia sera.
| Symbol | Fold change | 95% CI |
|
|---|---|---|---|
| TLR3 |
| (0.06, 0.64) |
|
| OSM |
| (0.00001, 0.79) |
|
| IK |
| (0.00001, 1.09) |
|
| FOS |
| (0.00001, 1.31) |
|
| PRLR |
| (0.00001, 0.96) |
|
| CD97 |
| (0.70, 0.93) |
|
|
| |||
| PRDX5 |
| (1.02, 1.27) |
|
| MIF |
| (1.02, 1.38) |
|
| IFNGR2 |
| (1.10, 1.35) |
|
| SDCBP |
| (1.01, 1.48) |
|
| NFX1 |
| (1.07, 1.43) |
|
| CD74 |
| (1.09, 1.43) |
|
| IL10RA |
| (1.12, 1.44) |
|
| BCL6 |
| (1.00, 1.63) |
|
| CCL28 |
| (1.00, 1.72) |
|
| NFE2L1 |
| (1.17, 1.55) |
|
| EPOR |
| (1.04, 1.69) |
|
| LTB4R |
| (1.13, 1.63) |
|
| CSF3R |
| (1.12, 1.70) |
|
| TLR4 |
| (1.19, 1.70) |
|
| CSF2RA |
| (1.26, 2.22) |
|
| IL18 |
| (0.95, 2.97) |
|
| IL36G |
| (0.36, 3.76) |
|
| IL37 |
| (0.00001, 4.50) |
|
| MEFV |
| (0.00001, 4.68) |
|
| PPBP |
| (0.81, 3.52) |
|
| CCL23 |
| (0.29, 4.21) |
|
| CXCL10 |
| (0.04, 4.85) |
|
| TLR9 |
| (0.06, 6.09) |
|
| SIGLEC1 |
| (0.00001, 6.98) |
|
Thirty genes showed alteration at least 2-fold or statistical significance (P < 0.05, unpaired t-test).
Genes differentially expressed in adipose tissue treated with nonobese preeclampsia sera (n = 5) versus matched control sera (n = 5).
| Functional categories | Genes | Reference |
|---|---|---|
| Immune response | ||
| Th2 predominance | BCL6 | [ |
| CCL28 | [ | |
| LTB4R | [ | |
| IL37 | [ | |
| Th1 predominance | IL18 | [ |
| CXCL10 | [ | |
| IK | [ | |
| Th17 predominance | IL36G | [ |
| Others | MEFV | [ |
| PPBP | [ | |
| CCL23 | [ | |
| SIGLEC1 | [ | |
| CD97 | [ | |
|
| ||
| Oxidative stress | ||
| Host defense | PRDX5 | [ |
| MIF | [ | |
| CD74 | [ | |
| NFE2L1 | [ | |
| CSF3R | [ | |
| Stress response | TLR4 | [ |
| TLR9 | [ | |
|
| ||
| Insulin resistance | ||
| Insulin sensitivity | IL10RA | [ |
| TLR3 | [ | |
| FOS | [ | |
| PRL | [ | |
| Insulin resistance | IFNGR2 | [ |
| NFX1 | [ | |
|
| ||
| Adipogenesis | ||
| Stimulation | SDCBP | [ |
| OSM | [ | |
| Reduction | EPOR | [ |
| CSF2RA | [ | |
Microarray analyses indicated that 24 upregulated genes and 6 downregulated genes in preeclampsia sera-treated adipose tissue were involved in immune response, oxidative stress, insulin resistance, and lipid metabolism. Gene expression was confirmed by RT-qPCR and independently validated.